ago for sick sinus syndrome in other hospital. On physical exam: His blood pressure was 150/80 mm Hg and heart rate 55 bpm. His lungs were clear on auscultation. Neurological exam was normal. The coronary angiography showed 75% stenosis in mid segment of right coronary artery (RCA), 50% in mid segment of anterior descending artery, 60% from ostium to proximal segment and subtotal occlusion of distal part of circumflex artery. A 3.0×24 mm drug-eluting stent was implanted in RCA and a 2.5×29 mm in circumflex artery after pre-dilation. 6 h later the patient complained pain in xiphoid process, back and neck. The monitor displayed blood pressure 150/80 mm Hg and heart rate 55 bpm. His patient was administered with simultaneous transfusion of 250 ml saline and blood pressure returned to and maintained at 100/60 mm Hg within 30 min. 4 h later, cardiac arrest occurred and the patient lost consciousness. Cardiopulmonary resuscitation was performed immediately and bedside echocardiography found cardiac tamponade. Pericardiocentesis was performed and 200 ml bloody fluid was withdrawn. Heart beat recovered and blood pressure returned to normal level. 10 h later, the patient woke up and was talkative, but could not move legs. He also had bladder and rectal incontinence. Neurological evaluation was as follows: cranial nerves without changes, absence of pain from umbilicus down, preserved deep sensitivity, deep tendon reflexes abolished and muscle tone decreased in legs. Computer tomography showed lacunar infarction of brain and degeneration of thoracic spinal column 5–9. Cerebrospinal fluid was clear with total proteins 230.6 mg/dl, WBC 7.0×106/l and IgG 580.0 mg/l. Anterior spinal artery syndrome was diagnosed and steroid, anti-platelet and anti-coagulation agents, vitamin B and butyrylphthalide were used. Rehabilitation therapy was introduced one month later. 3 months later, he regained urinary and fecal continence and could stand with a walker. The patient was discharged half year later.

**Conclusion** In older patients with diffuse arteriosclerosis, delayed cardiac tamponade may occur after PCI and induce persistent hypotension, even cardiac tamponade, and result in ASAS. There was a significant negative correlation between AngII and the activity of Ca2+-ATPase in RHR.

**Conclusions** The vascular remodelling of RHR may be associated with decreased vascular ATPases activities. Irbesartan can reverse vascular remodelling partially by increasing Ca2+-ATPase activity.

**e0340** ACTIONS OF IRBESARTAN ON ATPASE ACTIVITY AND ANGIOTENSIN II IN BLOOD VESSELS FROM RENAL HYPERTENSIVE RATS

doi:10.1136/hrt.2010.208967.340

Oian-Hu Shang, Ze-Bing Wu, Qian-Feng Jiang, Qin Wu. Institute of Clinical Medicine of Zunyi Medical College, Department of Cardiology, Affiliated Hospital of Zunyi Medical College; Department of Pharmacology, Zunyi Medical College, Zunyi Guizhou, China

**Objective** To explore the effects of irbesartan on activities of Na+-K+-ATPase, Ca2+-ATPase, Angiotensin II (AngII) and vascular remodelling in renal hypertensive rats (RHRs).

**Methods** Renovascular hypertension was induced by two kidney-one clip method. Eighteen RHRs were randomly divided into 3 groups: RHR model group (n=6), irbesartan treated group [50 mg/(kg d), n=6], withdrawal group (n=6). Six rats were included in sham operation group. Blood pressure was measured before and after using irbesartan. Thicknesses of vascular wall (TVW) of thoracic aorta and mesenteric artery were also found [thoracic aorta: (11.9±1.9) vs (7.5±1.6) μmol Fl/ (h·mg pro)]; mesenteric artery: (11.6±1.9) vs (8.2±0.8) μmol Fl/(h·mg pro), both p<0.01]. No change of Na+-K+-ATPase activity was found after irbesartan treatment. After one-week discontinuation of treatment, blood pressure was significantly elevated, the activity of Ca2+-ATPase of thoracic aorta [(7.6±1.4) μmol Fl/ (h·mg pro)] and mesenteric artery [(6.9±1.3) μmol Fl/(h·mg pro)] was decreased (both p<0.01). There was a significant negative correlation between AngII and the activity of Ca2+-ATPase in RHR.

**Conclusions** The vascular remodelling of RHR may be associated with decreased vascular ATPases activities. Irbesartan can reverse vascular remodelling partially by increasing Ca2+-ATPase activity.

**e0341** EFFECT OF FASTING GLUCOSE LEVELS ON MORTALITY RATE IN PATIENTS WITH DIABETES MELLITUS AND CORONARY ARTERY DISEASE UNDERGOING REVASCULARIZATION

doi:10.1136/hrt.2010.208967.341


**Objectives** We examined the association between glycaemic control determined by fasting glucose levels before elective PCI and the outcomes in diabetic patients undergoing elective revascularization.

**Background** Patients with diabetes mellitus (DM) have a worse clinical outcome after PCI than patients without DM, but whether optimal glycaemic control before PCI could improve the prognosis is not clear.

**Methods** The DESIRE-2 (Drug-Eluting Stent Impact on Revascularization-2) was a single-center registry of coronary revascularization in our institution between July 1st 2003 and Sep 30th 2005. A total of 434 diabetic patients undergoing elective PCI were enrolled in this study. Optimal glycaemic control was defined as fasting glucose <126 mg/dl, and suboptimal control was defined as fasting glucose ≥126 mg/dl. Median follow-up duration after the index intervention was 523 days.

**Results** The average patient age was 61.0±9.8 years; 69.8% of the patients were men. The patients with optimal glycaemic control were older than the suboptimal control group (62.1±9.46 vs 59.6±10.41). Compared with diabetic patients with optimal glycaemic control, those with suboptimal glycaemic control had similar rates of total mortality (5.5% vs 3.9%, p=0.762) and major adverse cardiac and cerebral events (15.9% vs 12.4%, p=0.308). In a multiple Cox regression analysis, total cholesterol level (HR 1.009, 95% CI 1.002 to 1.016, p=0.013) and number of lesion (HR 2.070, 95% CI 1.340 to 3.199, p=0.001) were significant independent predictors of MACCE.

**Conclusions** In diabetic patients undergoing elective PCI, optimal glycaemic control did not improve clinical prognosis. These data suggest that aggressive treatment of DM to achieve fasting glucose <126 mg/dl before PCI is not necessary.

**e0342** EFFECT OF ACARBOSE ON MYOCARDIAL PERFUSION IN PATIENTS WITH CORONARY HEART DISEASE AND IMPAIRED GLUCOSE TOLERANCE AFTER PCI: A CLINICAL TRIAL

doi:10.1136/hrt.2010.208967.342

Keng Wu, Hongmei Zhao. of Guangdong Medical College

**Objective** To study the effect of Acarbose on myocardial perfusion in revascularized patients with coronary heart disease and impaired glucose tolerance after percutaneous coronary intervention (PCI).
and investigate variations of lipid, glucose, and vascular endothelial growth factor (VEGF) levels myocardial perfusion images and cardiac function, as well as the possible mechanisms to improve myocardial perfusion.

**Methods** Total 102 cases were selected, 5 patients were lost. Finally 97 patients included, 77 males and 20 females, aged 56 ±13. Of whom, 30 cases suffered from acute myocardial infarction (AMI), 48 from acute coronary syndromes (ACS), and 19 from chronic stable angina pectoris. They were randomised into three groups, A (n = 33), B (n = 31), and C (n = 33) without differences in the baseline level. Normal adults were control group D (n = 30). Groups A and B were given by Acarbose 50 mg tid and 100 mg tid, respectively, Groups C and D were given by placebo, the treatment course lasted three months, and CHD patients of each group underwent the same basic treatments after PCI. Myocardial perfusion imaging and variations of blood lipid, IGT, VEGF levels, myocardial perfusion images and cardiac function were observed.

**Results** 1. The IGT had no statistically differences before treatments in A, B and C groups (p > 0.05). The changes of FPG and OGTT 2 h PG levels had statistically differences after treatments in A and B groups (p < 0.05), especially B group (p < 0.01); The changes of HbA1c had no statistically significant differences after treatments in the four groups (p > 0.05). The changes of lipid levels had no statistically differences (p > 0.05) before and after treatments in A, B, C and D groups, respectively. 2. A, B, C groups had the significantly higher plasma VEGF levels (203 ± 89 ng/l vs 77 ±52 ng/l, p < 0.01) than D group before treatments. The changes of VEGF levels had statistically differences after treatments in A and B groups (p < 0.05), especially B group (p < 0.01). The changes of VEGF levels had no statistically differences before and after treatments in C and D groups (p > 0.05). 3. The myocardial perfusion images and cardiac function had no statistically differences before and after treatments in A, B and C groups (p > 0.05). The changes of myocardial perfusion images had statistically differences after treatments in A and B groups (p < 0.05), especially B group (p < 0.01). The changes of cardiac function had statistically differences after treatments in A and B groups (p < 0.05), especially B group (p < 0.01); The changes of cardiac function had statistically differences after treatments in A and B groups (p < 0.05), there is no statistically differences after treatments between A and B (p < 0.05); The changes of myocardial perfusion images and cardiac function had no statistically differences in C group (p > 0.05).

**Conclusions** Acarbose can regulates IGT, improve myocardial perfusion images and cardiac function. The mechanisms may include reducing VEGF levels, suppressing endothelial hyperplasia, and improving the microcirculation.

**e0343** TRIPLE VERSUS DUAL ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION

doi:10.1136/hrt.2010.208967.343

Bin Hu, Yujie Zhou, Yuyang Liu, Dongmei Shi, Yingxin Zhao, Dean Jia. Beijing Anzhen Hospital

**Background** Following percutaneous coronary intervention (PCI), clopidogrel in addition to aspirin therapy leads to greater protection from thrombotic complications than aspirin alone. Whether triple antiplatelet therapy is superior or similar to dual antiplatelet therapy in patients with acute coronary syndrome undergoing PCI in the era of drug-eluting stents remains unclear.

**Objectives** To evaluate the effect of triple antiplatelet vs dual antiplatelet therapy in patients with acute coronary syndrome after PCI.

**Methods and Results** We collected consecutive 1203 acute coronary syndrome patients undergoing drug-eluting stents implantation. They received either dual (aspirin plus clopidogrel; dual group; n=682) or triple (aspirin plus clopidogrel plus cilostazol; triple group; n=521) antiplatelet therapy. The triple group received additional cilostazol at least for 1 month. Various major adverse cardiac events at 1 year were compared between these 2 groups. Compared with the dual group, the triple group had a similar incidence of major bleeding events but a significantly lower incidence of inhospital mortality. Clinical outcomes at 1 year showed that the triple group had significantly lower incidences of cardiac death and total major adverse cardiac events than the dual group.

**Conclusions** Triple antiplatelet therapy seems to be superior to dual antiplatelet therapy in patients ACS undergoing PCI with drug-eluting stents.

**e0344** THE MECHANISM RESEARCH OF FRP INHIBITS ENDOTHELIAL CELL APOPTOSIS

doi:10.1136/hrt.2010.208967.344

Shen Hua, Zhou Yujie, Liu Yuyang, Yang Shixwei, Gao Fei, Wang Zhijian, Shi Dongmei, Han Hongya, Ge Haitong, Liu Xiaoli. Department of Cardiology Beijing Anzhen Hospital Capital Medical University Beijing, China

**Background** Atherosclerosis is the most common cause of cardiovascular diseases in the world. Although the development of atherosclerosis appears to be the result of multiple maladaptive pathways, a particularly important factor in the pathogenesis of atherosclerosis is oxidised low density lipoprotein (ox-LDL), which contributes to endothelial damage. Data from our lab and others show that Follistatin related protein (FRP), which is expressed in the vasculature, has cardioprotective effects, suggesting that loss of FRP protection might play a role in the development of atherosclerosis.

**Objective** In the present study, we determined whether FRP overexpression protects against endothelial cell (EC) damage, an intermediate endpoint for atherosclerosis.

**Methods** We bred ApoE knockout (ApoE −/−) mice that were FRP+ transgenic (they overexpressed FRP). We compared them to control mice (their littermates). Data from our lab and others show that Follistatin related protein (FRP), which is expressed in the vasculature, has cardioprotective effects, suggesting that loss of FRP protection might play a role in the development of atherosclerosis.

**Results** After 16 weeks, ApoE (−/−) FRP (+) mice had significantly fewer apoptotic endothelial cells than controls. In vitro experiments showed that the effect of FRP on EC apoptosis was mediated by upregulation of expression of the antiapoptotic protein Bcl2.

**Conclusion** FRP overexpression maintains EC viability by preventing apoptosis via Bcl2 upregulation. FRP may be a novel therapeutic target for the prevention and treatment of vascular EC injury and of atherosclerosis.

**e0345** SERUM LIPOPROTEIN (A) IS POSITIVELY CORRELATED WITH CORONARY ARTERY CALCIFICATION IN LOW RISK CHINESE PATIENTS

doi:10.1136/hrt.2010.208967.345

Chengxing Shen, Jun Bao, Xiaoxia Chen, Genshan Ma. Zhongda Hospital southeast University

**Background** Prior studies indicated that lipoprotein (a) is an independent risk factor for coronary atherosclerosis, but the relationship of serum lipoprotein (a) and coronary artery calcification is still poorly understood in Chinese population.

**Objective** The present study is to investigate the human lipid profile of a single center (lipoprotein (a), other blood lipid levels) with the relationship of coronary artery calcification.

**Method** 388 patients suspected with coronary disease under coronary CT examinations from March 2007 to June 2009 in our